|
|
Article: Novuspharma SpA results of BBR 2778 study show potential.
- Article from:
- Drug Week
- Article date:
- August 9, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 AUG 9 - (NewsRx.com & NewsRx.net) -- Novuspharma SpA (NOV.MI), a biotechnology company focused on cancer, announced results from a preclinical study with BBR 2778 in a chronic model of multiple sclerosis.
The results were presented by Dr. Guido Cavaletti of the Bicocca University of Milan, together with colleagues and Novuspharma scientists, at the 12th Meeting of the European Neurological Society in Berlin June 22-26, 2002. BBR 2778 is Novuspharma's intercalating agent currently in phase III clinical trials for the treatment of non-Hodgkin lymphoma.
The aim of the preclinical experiments was to examine the effect of BBR 2778 in a chronic, ...